ホームポートフォリオウォッチリストコミュニティ発見スクリーナー
NOT FOR DISTRIBUTION

Laurus Labs Limited

NSEI:LAURUSLABS 株式レポート

時価総額:₹1.1t

  • 会社概要
    • 評価
    • 将来の成長
    • 過去の実績
    • 財務の健全性
    • 配当金
  • マネジメント
  • 所有権
  • その他の情報
  • 株式コミュニティ

Laurus Labs 将来の成長

Future 基準チェック /56

Laurus Labs利益と収益がそれぞれ年間21.6%と15.8%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に21.4% 19.5%なると予測されています。

主要情報

21.6%

収益成長率

19.48%

EPS成長率

Pharmaceuticals 収益成長18.6%
収益成長率15.8%
将来の株主資本利益率21.44%
アナリストカバレッジ

Good

最終更新日08 Sep 2026

今後の成長に関する最新情報

分析記事 • Jul 27

Results: Laurus Labs Limited Beat Earnings Expectations And Analysts Now Have New Forecasts

Laurus Labs Limited ( NSE:LAURUSLABS ) just released its quarterly report and things are looking bullish. The company...
分析記事 • Jan 28

Results: Laurus Labs Limited Beat Earnings Expectations And Analysts Now Have New Forecasts

Laurus Labs Limited ( NSE:LAURUSLABS ) just released its quarterly report and things are looking bullish. It was...

Recent updates

User avatar
ナラティブ更新 • Sep 03

LAURUSLABS: Rich Pricing And Lower Future P/E Will Limit Upside

The analyst fair value estimate for Laurus Labs has been updated from ₹540.50 to ₹657.00 as analysts factor in revised assumptions on growth, margins, and valuation multiples informed by recent sector research commentary. Analyst Commentary Recent Street research on education companies offers a useful reference point for how bearish analysts may approach a stock like Laurus Labs when concerns build around valuation, execution, or growth expectations.
User avatar
ナラティブ更新 • Aug 14

LAURUSLABS: Future Returns Will Depend On Resilient Margins Supporting Elevated P E Multiples

The Laurus Labs analyst price target has been updated from ₹1,044.00 to about ₹1,486.29. This change is supported by analyst assumptions that reflect higher revenue growth, stronger profit margins and a modestly higher future P/E, while keeping the discount rate broadly similar.
User avatar
ナラティブ更新 • Jul 31

LAURUSLABS: Higher Margin Outlook And Upcoming Results Dates Will Shape Future Appeal

Analysts have lifted the Laurus Labs fair value estimate from ₹1,370 to ₹1,980, reflecting updated assumptions for revenue growth, profit margins, and a slightly lower future P/E multiple. Analyst Commentary For Laurus Labs, the latest fair value revision sits against a broader backdrop of how bullish analysts are thinking about education and healthcare related names, including companies with similar growth and cash generation profiles.
分析記事 • Jul 27

Results: Laurus Labs Limited Beat Earnings Expectations And Analysts Now Have New Forecasts

Laurus Labs Limited ( NSE:LAURUSLABS ) just released its quarterly report and things are looking bullish. The company...
User avatar
ナラティブ更新 • Jul 17

LAURUSLABS: Lower Future P/E Assumptions Will Continue To Restrain Margin Upside

Analysts now see Laurus Labs' fair value at about ₹540.50, down from roughly ₹606.49. This reflects updated assumptions on future P/E levels as well as refreshed revenue growth and margin estimates.
User avatar
ナラティブ更新 • Jul 02

LAURUSLABS: Currency And Execution Risks Will Continue To Restrain Margin Upside

Analysts have revised their fair value estimate for Laurus Labs to ₹606.49 from ₹543.09, citing updated assumptions around revenue growth, profit margins, and a slightly higher future P/E multiple. What’s in the News for Laurus Labs Laurus Labs has scheduled a board meeting on April 30, 2026, at 14:00 IST to consider audited financial results for the quarter and year ended March 31, 2026, along with several corporate actions.
User avatar
ナラティブ更新 • Jun 18

LAURUSLABS: Dividend Moves And Governance Changes Will Shape Future Stock Appeal

Analysts have raised their fair value estimate for Laurus Labs to ₹1,370 from ₹1,270, reflecting updated assumptions around slightly adjusted growth, lower profit margins and a higher future P/E multiple in their latest models. Analyst Commentary Bullish analysts looking at Laurus Labs are focusing on how updated assumptions flow through to valuation, execution expectations and potential growth drivers.
User avatar
ナラティブ更新 • Jun 03

LAURUSLABS: Future Returns Will Depend On Sustained Confidence In Higher P E Multiples

Analysts have lifted their fair value estimate for Laurus Labs stock to ₹1,044 from ₹913, reflecting updated assumptions around modestly higher revenue growth, improved profit margins and revised future P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts see the higher fair value estimate as consistent with updated assumptions for Laurus Labs, where modestly higher revenue expectations support a richer long term P/E framework.
User avatar
ナラティブ更新 • Apr 30

LAURUSLABS: Upcoming Dividend Decision And Stable Assumptions Will Support Future Upside

Analysts have kept the Laurus Labs fair value estimate unchanged at ₹1,270, with small tweaks to revenue growth, profit margin and P/E assumptions. These reflect updated models rather than a shift in overall conviction.
User avatar
ナラティブ更新 • Apr 15

LAURUSLABS: Stronger Fundamentals And Upcoming Board Decisions Will Support Upside

Analysts have slightly reduced the Laurus Labs fair value estimate to ₹1,270 from ₹1,280 after updating assumptions on revenue growth, margins, and future P/E, while keeping the overall risk profile unchanged. Analyst Commentary Recent Street research on a different company, Laureate Education, still gives you a sense of how bullish analysts may think when they see improving fundamentals, supportive macro factors, or cleaner execution.
User avatar
ナラティブ更新 • Apr 01

LAURUSLABS: Currency And Execution Uncertainties Will Likely Cap Margin Upside

Analysts have made a small upward tweak to the Laurus Labs fair value estimate, with the price target moving from ₹540.28 to ₹543.09. This reflects updated assumptions on revenue growth and profitability.
User avatar
ナラティブ更新 • Mar 18

LAURUSLABS: Higher Margin Assumptions Will Likely Struggle Against Execution Risks

Narrative Update on Laurus Labs The updated analyst price target for Laurus Labs moves from about ₹330 to roughly ₹540. Analysts point to revised assumptions for margins and future P/E, along with broadly steady growth expectations, as key drivers of the change.
User avatar
ナラティブ更新 • Mar 04

LAURUSLABS: Steady Fair Value And Solid Fundamentals Will Support Upside

Analysts have kept their price target for Laurus Labs steady at ₹1,280, reflecting small adjustments to assumptions on discount rate, revenue growth, profit margin and future P/E. These changes are consistent with recent Street research, where targets shifted within a relatively tight range and analysts cited solid fundamentals alongside mixed near term signals.
User avatar
ナラティブ更新 • Feb 18

LAURUSLABS: Future Returns Will Rely On Confidence In Elevated P E Assumptions

Narrative Update: Laurus Labs Analyst Price Target Analysts have maintained their Laurus Labs price target at ₹913.47, citing largely unchanged assumptions around revenue, profit margins, discount rate, and forward P/E as the basis for keeping fair value steady. Analyst Commentary Analysts covering Laurus Labs are using a similar playbook to recent work on other education and healthcare names, where price targets are adjusted mainly on valuation inputs rather than big changes in growth assumptions.
User avatar
ナラティブ更新 • Feb 03

LAURUSLABS: Future Returns Will Depend On Confidence In Rich P E Assumptions

Analysts have lifted their fair value estimate for Laurus Labs from ₹863.13 to ₹913.47, citing slightly higher assumptions for revenue growth, profit margins and future P/E multiples, consistent with recent upward target revisions seen in related Street research. Analyst Commentary Bullish analysts point to the higher fair value estimate of ₹913.47 as support for a more constructive view on Laurus Labs, even though inputs are only slightly adjusted.
分析記事 • Jan 28

Results: Laurus Labs Limited Beat Earnings Expectations And Analysts Now Have New Forecasts

Laurus Labs Limited ( NSE:LAURUSLABS ) just released its quarterly report and things are looking bullish. It was...
分析記事 • Jan 25

Laurus Labs Limited's (NSE:LAURUSLABS) Popularity With Investors Is Under Threat From Overpricing

With a price-to-earnings (or "P/E") ratio of 65.1x Laurus Labs Limited ( NSE:LAURUSLABS ) may be sending very bearish...
User avatar
ナラティブ更新 • Jan 20

LAURUSLABS: Future Returns Will Depend On Rich P E Assumptions Holding

Analysts have lifted their price target for Laurus Labs to ₹863 from about ₹822, reflecting updated assumptions on fair value, profit margins, and future P/E multiples. Analyst Commentary Bullish Takeaways Bullish analysts view the higher price target as a sign that current assumptions on Laurus Labs' fair value leave room for upside if the company executes consistently on profitability.
User avatar
ナラティブ更新 • Jan 06

LAURUSLABS: Interim Dividend And Higher P E Multiple Will Support Upside

Analysts have raised their price target on Laurus Labs from ₹1,025 to ₹1,280, citing updated assumptions for revenue growth, profit margins, and a higher future P/E multiple. What's in the News The Board of Directors approved an interim dividend of ₹0.80 per equity share of face value ₹2 for the 2025-26 financial year at the meeting held on October 23, 2025 (company filing).
User avatar
ナラティブ更新 • Dec 21

LAURUSLABS: Interim Dividend May Not Offset Softer Margins Ahead

Analysts have moderately raised their price target on Laurus Labs from ₹303.09 to ₹330.21, citing a slightly higher justified valuation multiple that more than offsets their marginally softer assumptions on revenue growth and profit margins. What's in the News The Board approved an interim dividend of INR 0.80 per equity share (40 percent of the face value of INR 2) for FY 2025-26, signaling confidence in cash flows and shareholder returns (company filing).
User avatar
ナラティブ更新 • Dec 07

LAURUSLABS: Future Returns Will Likely Hinge On Managing Execution Risks

Analysts have modestly increased their price target for Laurus Labs while maintaining fair value at ₹821.93, citing expectations of sustained earnings growth supported by a solid balance sheet, margin expansion, and revenue momentum from new market opportunities. Analyst Commentary Street research on comparable growth stories in the education and healthcare sectors highlights themes that are directly relevant for Laurus Labs, particularly around how markets price in multi year earnings expansion, balance sheet strength, and scalability in new markets.
User avatar
ナラティブ更新 • Nov 23

LAURUSLABS: Future Revenue Upside May Be Limited By Execution Risks

Analysts have raised their price target for Laurus Labs slightly, from ₹815.86 to ₹821.93. They cite expectations of stronger revenue growth supported by a robust balance sheet and expanding opportunities in new markets.
User avatar
ナラティブ更新 • Nov 04

LAURUSLABS: Margin Pressures From Rising Input Costs Will Weigh On Earnings

Analysts have raised their fair value price target for Laurus Labs from ₹724.14 to ₹815.86. They cite increased profitability outlook and sustained margin growth as key drivers for the revision.
分析記事 • Oct 30

Laurus Labs' (NSE:LAURUSLABS) Dividend Will Be ₹0.80

Laurus Labs Limited ( NSE:LAURUSLABS ) will pay a dividend of ₹0.80 on the 22nd of November. Even though the dividend...
User avatar
ナラティブ更新 • Oct 21

Analysts Cite Growth Momentum and Strong Balance Sheet in Raising Laurus Labs Valuation Estimates

Analysts have raised their fair value estimate for Laurus Labs from ₹694.85 to ₹724.14. They cite continued revenue growth momentum and a strong balance sheet as key drivers for this upward revision.
分析記事 • Oct 19

With Laurus Labs Limited (NSE:LAURUSLABS) It Looks Like You'll Get What You Pay For

Laurus Labs Limited's ( NSE:LAURUSLABS ) price-to-sales (or "P/S") ratio of 8.2x may look like a poor investment...
User avatar
新しいナラティブ • Jan 26

CDMO Expansion May Impact Near-Term Margins But Pave Way For Future Revenue Streams

Heavy investment in CDMO and microbial precision initiatives may lead to revenue delays and short-term margin compression due to underutilized assets.

業績と収益の成長予測

NSEI:LAURUSLABS - アナリストの将来予測と過去の財務データ ( )INR Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
3/31/2029114,36221,3918,543N/A8
3/31/202895,48915,7194,449N/A15
3/31/202783,39613,714-3,973N/A12
6/30/202672,69610,934N/AN/AN/A
3/31/202668,1298,8885,53616,235N/A
12/31/202567,2168,433N/AN/AN/A
9/30/202563,5846,8407,69616,375N/A
6/30/202559,2865,088N/AN/AN/A
3/31/202555,5403,583-3936,017N/A
12/31/202452,7332,003N/AN/AN/A
9/30/202450,5321,311-3,2772,489N/A
6/30/202450,5401,482N/AN/AN/A
3/31/202450,4081,606-1266,657N/A
12/31/202349,8211,879N/AN/AN/A
9/30/202353,3203,6782,87012,248N/A
6/30/202356,8345,637N/AN/AN/A
3/31/202360,4067,901379,939N/A
12/31/202260,8459,176N/AN/AN/A
9/30/202255,6848,683138,393N/A
6/30/202251,9608,374N/AN/AN/A
3/31/202249,3568,2753439,111N/A
12/31/202149,2278,937N/AN/AN/A
9/30/202151,82310,128-1,7057,112N/A
6/30/202151,17710,532N/AN/AN/A
3/31/202148,1359,8364427,330N/A
12/31/202042,4077,971N/AN/AN/A
9/30/202036,8195,9771,5485,427N/A
6/30/202032,5554,120N/AN/AN/A
3/31/202028,3172,553N/A3,474N/A
12/31/201926,2771,883N/AN/AN/A
9/30/201924,2761,326N/A3,538N/A
6/30/201923,035923N/AN/AN/A
3/31/201922,919938N/A2,977N/A
12/31/201822,170957N/AN/AN/A
9/30/201821,6651,127N/AN/AN/A
6/30/201821,1681,453N/AN/AN/A
3/31/201820,5621,676N/A3,425N/A
12/31/201719,6871,917N/AN/AN/A
9/30/201719,9542,019N/AN/AN/A
6/30/201719,7332,014N/AN/AN/A
3/31/201719,0461,881N/A3,320N/A
3/31/201617,7761,337N/A1,820N/A

アナリストによる今後の成長予測

収入対貯蓄率: LAURUSLABSの予測収益成長率 (年間21.6% ) は 貯蓄率 ( 6.9% ) を上回っています。

収益対市場: LAURUSLABSの収益 ( 21.6% ) はIndian市場 ( 16.8% ) よりも速いペースで成長すると予測されています。

高成長収益: LAURUSLABSの収益は今後 3 年間で 大幅に 増加すると予想されています。

収益対市場: LAURUSLABSの収益 ( 15.8% ) Indian市場 ( 11.3% ) よりも速いペースで成長すると予測されています。

高い収益成長: LAURUSLABSの収益 ( 15.8% ) 20%よりも低い成長が予測されています。


一株当たり利益成長率予想


将来の株主資本利益率

将来のROE: LAURUSLABSの 自己資本利益率 は、3年後には高くなると予測されています ( 21.4 %)


成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日(UTC時間)
企業分析2026/09/14 18:09
終値2026/09/11 00:00
収益2026/06/30
年間収益2026/03/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
  • SECフォーム10-K
  • SECフォーム10-Q
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
  • アナリストリサーチレポート
  • Blue Matrix
市場価格30年
  • 株価
  • 配当、分割、措置
  • ICEマーケットデータ
  • SECフォームS-1
所有権10年
  • トップ株主
  • インサイダー取引
  • SECフォーム4
  • SECフォーム13D
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
  • SECフォーム10-K
  • SECフォームDEF 14A
主な進展10年
  • 会社からのお知らせ
  • SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Laurus Labs Limited 15 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。26

アナリスト機関
Rohit Bhat360 ONE Capital Market Private Limited
Ashwin MehtaAmbit Capital
null nullAntique Stockbroking Ltd.

どこでもより良い投資判断を

スキャンしてダウンロード
App Store を開くGoogle Play を開く
Chrome ウェブストア
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
データソースを見る
市場
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
投資のアイデア
  • 割安企業
  • 配当優良企業
  • インサイダー買い
  • 原子力
  • 自律走行車
  • 人工知能
  • 暗号資産とブロックチェーン
  • サイバーセキュリティ
  • さらにアイデア
株価コミュニティ
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
機能とツール
  • ポートフォリオ・トラッカー
  • ストックスクリーナー&アラート
  • 語りと公正な値
  • 配当金計算機
ニュース & 発見
  • 最新の在庫ニュース
  • グローバルマーケットインサイト
  • The Foxhole ブログ
  • 投資のアイデア
  • コミュニティの物語
  • 新着情報
Simply Wall St
  • プランと料金
  • 広告
  • 会社概要
  • お問い合わせ
  • 採用情報
  • ヘルプセンター
  • 株式投資を学ぶ
  • アフィリエイト・プログラム
  • ビジネス
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • ご利用条件
  • プライバシーポリシー
  • AI利用規約
  • 金融サービスガイド